BPMC

MD Anderson and Blueprint Medicines Announce Strategic Collaboration to Accelerate BLU-222 Development

Blueprint Medicines to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021

Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM

FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis

Blueprint Medicines to Present at Upcoming Investor Conferences

Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer and Other Advanced Solid Tumors